Baxter International Inc (BAX-N) Stock Predictions - Stockchase
WATCH LIST
33
Baxter International Inc (BAX-N)

ON STOCKCHASE SINCE Aug 2006

biotechnology/pharmaceutical

Baxter International Inc

BAX-N

9 watching          
Join the Discussion

Baxter International Inc (BAX-N) SAVE Apr, 19, 2019, 9:04 am

74.33 0.06 (0.08%)

About Baxter International Inc (BAX-N)

Baxter International Inc. is a Fortune 500 American health care company with headquarters in Deerfield, Illinois. More at Wikipedia

What the experts are saying about BAX-N



  • All
  • Filtered
Signal Opinion Expert
DON'T BUY
Baxter International Inc(BAX-N) 

September 11, 2018

She owned this a few years ago. It has done well recently, as has the US health sector generally. Its new CEO focused on new product developments that would generate better growth. The company is now fully valued, selling above historical valuation levels. She would consider it on a significant pullback.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

She owned this a few years ago. It has done well recently, as has the US health sector generally. Its new CEO focused on new product developments that would generate better growth. The company is now fully valued, selling above historical valuation levels. She would consider it on a significant pullback.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$75.870
Owned Owned
No

COMMENT

Dialysis equipment amounts to 40% of their business. Sold his shares too early. They've had a great run. High 24x forward earnings. But the stock warrants a second look. Dividend just under 1% with negative growth and could
continue downward. Nine consecutive quarterly beats.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Dialysis equipment amounts to 40% of their business. Sold his shares too early. They've had a great run. High 24x forward earnings. But the stock warrants a second look. Dividend just under 1% with negative growth and could
continue downward. Nine consecutive quarterly beats.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$66.460
Owned Owned
No

PAST TOP PICK

(A Top Pick Sept 28/16. Up 35%.) Believes he will be holding this for quite a long time. They are the best in the medical devices/medical supply. Expects it might go sideways for a while and it would be a Buy on any weakness.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Sept 28/16. Up 35%.) Believes he will be holding this for quite a long time. They are the best in the medical devices/medical supply. Expects it might go sideways for a while and it would be a Buy on any weakness.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$63.880
Owned Owned
Yes

PAST TOP PICK
Baxter International Inc(BAX-N) 

September 21, 2017

(A Top Pick June 30/16. Up 42%.) He still likes this. Healthcare is one of the few sectors, if you can deal with the volatility, that is in a secular bull market that began in 2012. He still likes this today, and it is still a Buy.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick June 30/16. Up 42%.) He still likes this. Healthcare is one of the few sectors, if you can deal with the volatility, that is in a secular bull market that began in 2012. He still likes this today, and it is still a Buy.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$63.380
Owned Owned
Yes

TOP PICK
Baxter International Inc(BAX-N) 

September 28, 2016

Very big in kidney medicine. Healthcare is a really good space to be in. One of the few spaces that is in a secular bull market. This company has some pricing power and some really big competitive advantages that are going to be recognized by the market. Dividend yield of 1.1%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Very big in kidney medicine. Healthcare is a really good space to be in. One of the few spaces that is in a secular bull market. This company has some pricing power and some really big competitive advantages that are going to be recognized by the market. Dividend yield of 1.1%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$47.920
Owned Owned
Yes

TOP PICK

This supplies hospitals with tons of different stuff and there is a focus on renal, things related to the kidneys. Had a sideways move from 2013 to early 2016, and then broke out. Feels it is really good at these prices. They had a really good Q1 and raised their sales and earnings guidance, and increased their expectations for operational improvements. Has a $65 target on this, but thinks that is a little conservative. Dividend yield of 1.15%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

This supplies hospitals with tons of different stuff and there is a focus on renal, things related to the kidneys. Had a sideways move from 2013 to early 2016, and then broke out. Feels it is really good at these prices. They had a really good Q1 and raised their sales and earnings guidance, and increased their expectations for operational improvements. Has a $65 target on this, but thinks that is a little conservative. Dividend yield of 1.15%.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$45.220
Owned Owned
Yes

COMMENT

Doesn’t follow this closely. Scores particularly well on his valuation metrics. Very high ROE’s at 30%. PE of only 9X, which is a very strong valuation metric for him. It beat recently on earnings. 5.4% dividend yield. However, momentum is where it falls down for him, and it scores in the bottom 10, which keeps him sidelined.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Doesn’t follow this closely. Scores particularly well on his valuation metrics. Very high ROE’s at 30%. PE of only 9X, which is a very strong valuation metric for him. It beat recently on earnings. 5.4% dividend yield. However, momentum is where it falls down for him, and it scores in the bottom 10, which keeps him sidelined.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Mann

CIO & Co-F, Edgehill Patners...

Price Price
$37.110
Owned Owned
No

BUY

(Market Call Minute) There is a lot thrown away with every operation.  It is really expensive stuff.  BAX-N makes it.  Disposable medical supplies.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Market Call Minute) There is a lot thrown away with every operation.  It is really expensive stuff.  BAX-N makes it.  Disposable medical supplies.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Baskin

President, Baskin Wealth Manage...

Price Price
$38.300
Owned Owned
No

COMMENT

Medical devices and products. Has a decent dividend yield and has grown is profits at a pretty decent pace. Dealing with some headwinds from a currency perspective. Has been able to hold its profit margins pretty consistently. Good strong balance sheet. Earnings forecasts for next year are trending lower. Trading at about 14X earnings, this is below market multiple. A good grower and this is the kind of stock that eventually rewards investors. You could also look at Thermo Fisher Scientific (TMO-N).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Medical devices and products. Has a decent dividend yield and has grown is profits at a pretty decent pace. Dealing with some headwinds from a currency perspective. Has been able to hold its profit margins pretty consistently. Good strong balance sheet. Earnings forecasts for next year are trending lower. Trading at about 14X earnings, this is below market multiple. A good grower and this is the kind of stock that eventually rewards investors. You could also look at Thermo Fisher Scientific (TMO-N).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John O'Connell,

Chairman a, Davis Rea...

Price Price
$64.080
Owned Owned
No

DON'T BUY

Used to own it.  She saw better opportunities.  There is not a lot of pricing leverage because there are strong competitors in that business. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Used to own it.  She saw better opportunities.  There is not a lot of pricing leverage because there are strong competitors in that business. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Christine Poole

CEO & Mana, GlobeInvest Capital ...

Price Price
$67.000
Owned Owned
No

BUY

From a valuation perspective, this is one of his favourite stocks. Company has announced that it is going to split itself into 2 main businesses, products for haemophiliacs and a kidney dialysis business. They expect that to happen in 2015. This still offers good value as he thinks the stock is easily worth in the low $80’s.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

From a valuation perspective, this is one of his favourite stocks. Company has announced that it is going to split itself into 2 main businesses, products for haemophiliacs and a kidney dialysis business. They expect that to happen in 2015. This still offers good value as he thinks the stock is easily worth in the low $80’s.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Charles Lannon

Director o, Toron Investment Man...

Price Price
$73.260
Owned Owned
Yes

BUY

(Market Call Minute) Likes it here.  Growth is good for healthcare stocks.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Market Call Minute) Likes it here.  Growth is good for healthcare stocks.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Charles Lannon

Director o, Toron Investment Man...

Price Price
$65.900
Owned Owned
Yes

HOLD

Diversified US healthcare stock.  Biggest player in Kidney Dialysis.  Earnings came in recently a little lighter than the street was looking for but he still likes it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Diversified US healthcare stock.  Biggest player in Kidney Dialysis.  Earnings came in recently a little lighter than the street was looking for but he still likes it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$67.560
Owned Owned
Yes

HOLD
Likes it but will not buy more right now. It’s Christine Pool’s stock.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Likes it but will not buy more right now. It’s Christine Pool’s stock.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Peter Brieger

Chairman &, GlobeInvestment Capi...

Price Price
$54.510
Owned Owned
Yes

PAST TOP PICK
(A Top Pick Aug 11/10. Up 33.66%.) Hospital supply company. Very big in the kidney dialysis market. Likes the demographics.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Aug 11/10. Up 33.66%.) Hospital supply company. Very big in the kidney dialysis market. Likes the demographics.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Norman Levine

Managing D, Portfolio Management...

Price Price
$59.230
Owned Owned
Yes

Showing 1 to 15 of 33 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days